enGene Therapeutics Warrants
ENGNW
11 hedge funds and large institutions have $12.9M invested in enGene Therapeutics Warrants in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
2% more ownership
Funds ownership: 46.54% → 48.54% (+2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less capital invested
Capital invested by funds: $13.9M → $12.9M (-$990K)
21% less funds holding
Funds holding: 14 → 11 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOCH
Blue Owl Capital Holdings
New York
|
+$1.41M |
| 2 |
LP
LMR Partners
London,
United Kingdom
|
+$715K |
| 3 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$487K |
| 4 |
ICM
Ionic Capital Management
New York
|
+$49.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$844K |
| 2 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$420K |
| 3 |
Calamos Advisors
Naperville,
Illinois
|
-$418K |
| 4 |
SCM
Saba Capital Management
New York
|
-$288K |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$48K |
ENGNW Hedge Fund Activity: Q1 2026 in Review
11 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics Warrants (ENGNW) for Q1 2026, worth a combined $12.9M — down 7.1% from $13.9M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ENGNW and 2 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Blue Owl Capital Holdings, adding an estimated $1.41M. The largest seller was Vivo Capital, exiting entirely with an estimated $844K sold.
- 11 institutional investors held enGene Therapeutics Warrants (ENGNW) as of Q1 2026, down from 14 in Q4 2025.
- Funds reported $12.9M of enGene Therapeutics Warrants stock for Q1 2026, down 7.1% quarter-over-quarter.
- 2 funds opened new enGene Therapeutics Warrants positions in Q1 2026 and 5 closed out, a net change of -3 holders.
- The largest enGene Therapeutics Warrants buyer in Q1 2026 was Blue Owl Capital Holdings, an estimated $1.41M added.
- The largest enGene Therapeutics Warrants seller in Q1 2026 was Vivo Capital, an estimated $844K sold.
Based on aggregated 13F filings for Q1 2026.